Partnership to focus on developing immunotherapies for patients with cancer.
F-star Therapeutics, a biopharmaceutical company, has announced a strategic partnership with Takeda. As per the deal, the organizations will jointly research and develop novel Fcab ™ domains against undisclosed immuno-oncology targets for cancer patients, with Takeda receiving exclusive royalty-bearing license to research, develop, and commercialize antibodies incorporating Fcab domains. F-star will retain the rights on other domains.
“We are delighted to expand our relationship with Takeda who shares our vision of developing pioneering multi-specific immunotherapies so more people with cancer can live longer with improved lives,” said Neil Brewis, PhD, chief scientific officer, F-star Therapeutics. “This strategic collaboration leverages the capabilities of both companies by combining F-star’s clinically validated Fcab™ and mAb² ™ platforms with Takeda’s unique understanding of the immune system and its ability to progress drugs to the clinic.”
Reference: F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies. GlobeNewswire. July 5, 2023. Accessed July 6, 2023. https://www.globenewswire.com/news-release/2023/07/05/2699446/0/en/F-star-an-invoX-Company-Announces-Strategic-Collaboration-and-Licence-Agreement-with-Takeda-to-Discover-and-Develop-Next-Generation-Multi-Specific-Antibodies.html
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.